Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Study acronym: PREDI-CGRP
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 5 more changesShow less
    • Study completion pushed from Jul 2026 to Dec 2026
    • Primary completion date changed from estimate of Jul 2026 to Jul 31, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised at 7 of 7 sites
  2. Primary and study completion dates: Dec 2025 to Jul 2026v3
  3. Primary completion date: Jun 2025 to Dec 2025
    • Site details revised at 1 of 7 sites
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Trial Details
NCT Number NCT06459648
Lead Sponsor Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Conditions
(from sponsor)		 Migraine
Related terms Headache, Migraine Disorders
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov